Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Strychnos Total Alkaloids Vesicle Gel is a topical traditional Chinese medicine (TCM) candidate developed by Beijing Yingkerei Pharmaceutical Technology for the treatment of pain and inflammation. The formulation utilizes a vesicle-based delivery system, such as liposomes or ethosomes, to encapsulate the total alkaloids extracted from *Strychnos nux-vomica*, which primarily include strychnine and brucine. This advanced delivery approach is designed to enhance transdermal penetration and provide localized therapeutic effects while significantly reducing the systemic toxicity typically associated with the oral administration of *Strychnos* alkaloids. Mechanistically, these alkaloids act as potent analgesics, with strychnine serving as a competitive antagonist of the inhibitory glycine receptor (GlyR) in the central nervous system and peripheral tissues, thereby modulating pain signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on strychnos total alkaloids vesicle gel.